Ignite Creation Date:
2024-05-05 @ 11:03 PM
Last Modification Date:
2024-10-26 @ 10:28 AM
Study NCT ID:
NCT01245816
Status:
WITHDRAWN
Last Update Posted:
2015-04-24
First Post:
2010-11-19
Brief Title:
A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis FAP
Sponsor:
Cancer Prevention Pharmaceuticals Inc
Organization:
Cancer Prevention Pharmaceuticals Inc
Organization Data
Organization:
Cancer Prevention Pharmaceuticals Inc
Class:
INDUSTRY
Study ID:
CPP FAP-301
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Cancer Prevention Pharmaceuticals Inc
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
None
Responsible Party Affiliation:
None
Old Name:
Jeffrey Jacob CEO
Old Organization:
Cancer Prevention Pharmaceuticals Inc